Rheumatology

Biologics

Questions discussed in this category

Would you stop belimumab in a patient with SLE starting ravulizumab (C5 inhibitor) for myasthenia gravis due to concern for additive immunosuppression?

3 Answers available

What is your approach to management of elevated liver enzymes in patients who recently started treatment with tocilizumab?

1 Answer available

How long would you wait to start another biologic agent after Rituximab administration in patients with dermatomyositis and refractory inflammatory arthritis (intolerant to traditional DMARDs)?

Patient with dermatomyositis on rituximab with refractory inflammatory arthritis. Intolerant of traditional DMARDs such as methotrexate, leflunomide, ...

1 Answer available

What would be the main indications for opting for biosimilars over an original biologic, outside of insurance barriers?

Are there any instances where you would prefer a biosimilar rather than the reference product?

2 Answers available

Which medications have the lowest risk of tuberculosis reactivation in patients with uncertain tuberculosis history and active rheumatologic disease?

2 Answers available

Would you start a TNF-I for seronegative non-erosive RA in a patient with positive ANA and sun sensitivity without other SLE features?

1 Answer available

Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?

1 Answer available

What is the biologic of choice in a patient with RA and myasthenia gravis?

1 Answer available

How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

2 Answers available

What is your approach to dental prophylaxis for patients on biologics?

1 Answer available

Papers discussed in this category

Arthritis care & research, 2012-05

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Arthritis Rheumatol, 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

N Engl J Med,

Clinical practice. Care of the asplenic patient.

Mediterr J Rheumatol, 2020 Jun 11

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Front Immunol, 2021 Jul 14

Complement C4, Infections, and Autoimmune Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.

Arthritis and rheumatism, 2011-03

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.

The Journal of rheumatology, 2013-05

Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.

Rheumatology

Biologics

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology